CollaGenex Pharmaceuticals has suspended enrollment in a phase II dose-finding study incyclinide for the treatment of acne after one patient experienced significant phototoxicity.
From: www.pharmaceutical-business-review.com
CollaGenex suspends patient enrollment in acne trial
Posted by Ruslan Abuzant at 8:10 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment